Potential Approaches to Treatment Switching in HR+/HER2- mBC
Experts share how they approach management of patients with disease progression on first-line endocrine therapy, with a focus on ESR1 mutation testing and identifying who might be suitable for treatment with the oral SERD elacestrant.
EP: 1.Standard-of-Care Treatment Approaches for HR+/HER2 Early Breast Cancer
EP: 2.Unmet Needs in Early-Stage HR+/HER2- Breast Cancer
EP: 3.Recent Data on Neoadjuvant Therapy in HR+/HER2- Breast Cancer
EP: 4.Circulating Tumor DNA as a Prognostic Marker in HR+/HER2- Breast Cancer
EP: 5.Recent Data on Adjuvant Therapies in HR+/HER2- Breast Cancer
EP: 6.Managing Abemaciclib-Associated Toxicities in HR+/HER2- Early Breast Cancer
EP: 7.Treatment and Dose Optimization in HR+/HER2- Early Breast Cancer
EP: 8.CDK4/6 Inhibitors in the Metastatic Breast Cancer Setting
EP: 9.Real-World Data on CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer and Ongoing Trials
EP: 10.The SONIA Trial: Exploring CDK4/6 Inhibitor Efficacy in the First- and Second-Line Settings
EP: 11.Ribociclib/ET versus Chemotherapy in Premenopausal Patients: RIGHT Choice
EP: 12.Potential Approaches to Treatment Switching in HR+/HER2- mBC
EP: 13.Addressing Disease Progression on ET: Data Updates and Ongoing Trials
EP: 14.HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathway
EP: 15.Biomarker Testing Practices in HR+/HER2- Breast Cancer
EP: 16.Data Updates on Sacituzumab Govitecan
EP: 17.Practical Considerations for ADC Selection in HR+/HER2- mBC
EP: 18.Looking Towards The Future of HR+/HER2- Breast Cancer
Transcript:
Komal Jhaveri, MD, FACP: Switching over from our first-line metastatic setting where we’ve definitely now established that we use CDK4/6 inhibitors and novel SERDs [selective estrogen receptor disruptors] might be a good endocrine partner of choice in the future based on these trials. When patients progress in the first-line metastatic setting and you have to think about what would you offer them next, what kind of factors or characteristics do you keep in mind when you’re making those choices?
Timothy Pluard, MD: [With] progression on first-line therapy, we start to think, what are the driver mutations? Is there an ESR1 [mutation] that has emerged during the first-line therapy, PI3 kinase inhibitors? Do they have a PIK3CA mutation that could be targeted? There’s the population that is 6 months or less on CDK4/6 inhibitors in the first line, and that’s a group of patients we know do very poorly on second-line endocrine therapy. So, it’s even more imperative to try to identify a potentially targetable mutation in those patients.
I think we’ve gotten away from just single-agent endocrine therapy, although now we have elacestrant, which could be a potential single-agent SERD that targets ESR1 mutations. So, I think as we start to get these new novel SERDs, the SERMs [selective estrogen receptor modulators], and the other anti-estrogens that may be more effective against ESR1, I think we’ll be able to use those and then start combining them again with CDK4/6 inhibitors, perhaps in the second line.
Komal Jhaveri, MD, FACP: Dr Bardia was the one who led the phase 3 EMERALD trial [NCT03778931], [which] led to the approval of elacestrant. Dr Bardia could you mention from your perspective who is the right patient according [who] should be provided with the prescription with elacestrant in clinic today? What more could we be thinking about or doing for those patients where you don’t think they might be appropriate, and who they would be?
Aditya Bardia, MD, MPH: A good question. In general, I tend to follow evidence, and you know, based on the FDA label, elacestrant should be used in the second-line-plus setting for a patient who has detectable ESR1 mutation. So that’s where I would consider this drug. If you look at the EMERALD results and look at the progression-free survival, you see that in both arms there was an initial drop in the curves and then separation, which is consistent across all the studies that have been done in the second-line setting with endocrine monotherapy, because there’s a subset of patients who do not have ER [estrogen receptor]-driven tumors or ER-dependent tumors. In that setting, single-agent monotherapy with any endocrine agent is not going to work. The next question is, can we identify that? Ideally it should be some genomic factor and maybe in the future we’ll have some genomic predictor. We looked at clinical pathological features in terms of prior duration of CDK4/6, and it does appear that prior duration of CDK4/6 is a surrogate marker for endocrine sensitivity. Like any other surrogate markers, it’s not perfect, but at least [it] gives us more insight in terms of a population that might derive longer benefit with elacestrant. For example, patients who are on CDK4/6 inhibitor for at least 12 months, the median PFS [progression-free survival] with elacestrant was about 8 months as compared to about 2 months with standard therapy. So, maybe that’s another factor to consider in clinic when using elacestrant. In terms of what I’m excited about, I’m excited about combinations as we were discussing combining elacestrant with a CDK4/6 inhibitor. Hopefully, we’ll have better outcomes than [with] monotherapy.
Komal Jhaveri, MD, FACP: I think there are ongoing trials with elacestrant. The ELEVATE trial [NCT05563220] is evaluating multiple combinations.
Transcript edited for clarity.
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
